This study shows that neoadjuvant treatment with chemotherapy, trastuzumab, and pertuzumab instead of chemotherapy and trastuzumab is of significant benefit in early-stage HER2-positive female breast cancer patients. This evidence concerns the gene ERBB2 and breast cancer.